ACY 241 in Combination With Paclitaxel in Patients With Advanced Solid Tumors
Status:
Completed
Trial end date:
2019-10-04
Target enrollment:
Participant gender:
Summary
This is a Phase 1b, multicenter, single arm, open label, dose escalation study to determine
the MTD and evaluate the safety and preliminary antitumor activity of orally (PO)
administered ACY 241 in combination with intravenously (IV) administered paclitaxel in
eligible patients with advanced solid tumors.